Long-term melatonin use for insomnia was associated with a higher hazard of heart failure (HF), an increase in HF hospitalizations and a doubling of all-cause mortality over five years, according to a ...

Please note: the ACC uses a January - December calendar, which is indicated in the estimated release dates below. The policies appear in order based on their estimated release date.

Food supplementation for patients following a heart failure (HF)-related hospitalization was both feasible and acceptable and associated with clinically meaningful improvement in quality of life ...

Beta-blocker therapy following myocardial infarction (MI) was the primary focus of a hot line session at ESC Congress 2025. Study investigators presented findings from the REBOOT-CNIC and ...

Digitoxin in addition to guideline-directed medical therapy, reduced the risk of a composite of all-cause death and hospitalization for worsening heart failure (HF) among patients with advanced HF and ...

Popular anti-obesity drugs continue to show cardiovascular benefits beyond weight loss, according to new research published in JACC and simultaneously presented at AHA 2024. Among the highlights: ...

The U.S. Food and Drug Administration (FDA) has approved acoramidis as a treatment to help reduce cardiovascular death and cardiovascular-related hospitalization in patients with transthyretin amyloid ...

A new nasal spray form of bumetanide may reduce the tissue swelling caused by heart failure (HF) as effectively as the standard oral and intravenous formulations of the loop diuretic, based on ...

A significant prevalence of elevated blood pressure (BP) measurements was found among young athletes during community heart screenings, according to research presented during ACC's Care of the ...

Mavacamten did not significantly improve exercise capacity as assessed by peak oxygen uptake or improve patient-reported health status compared with placebo in patients with symptomatic nonobstructive ...

Black Americans suffered nearly 800,000 excess age-adjusted deaths and 24 million excess years of potential life lost due to cardiovascular disease from 2000 to 2022, compared with their White ...

The SGLT2 inhibitor empagliflozin did not lower the risk of a first hospitalization for heart failure (HF) or death from any cause among patients with an increased risk for HF following acute ...